Key result
Resveratrol pretreatment alleviated coronary microembolization-induced myocardial damage by improving cardiac dysfunction and lowering myocardial injury biomarkers and microinfarct size in rats.
Why the study?
Coronary microembolization leads to cardiac dysfunction and apoptosis, but the role and mechanisms of cardioprotective resveratrol in coronary microembolization were not clearly understood.
Does resveratrol pretreatment reduce myocardial injury and apoptosis in a rat model of coronary microembolization?
RCT (n=40)
Randomly selected and categorized
Does resveratrol pretreatment reduce myocardial injury and apoptosis in a rat model of coronary microembolization?
Resveratrol pretreatment protects against coronary microembolization-induced myocardial injury and apoptosis in rats by activating the PI3K/Akt/GSK-3β signaling cascade.
Resveratrol may mitigate microembolization injury in rats; hypothesis-generating and leaves open clinical translation.
PURPOSE: Coronary microembolization (CME) is associated with progressive cardiac dysfunction, myocardial inflammation, and apoptosis. Resveratrol (RES) has a considerable role in cardioprotection. However, the contribution and possible mechanisms of RES in CME have not been clearly understood. METHODS: In the current study, 40 SD rats were randomly selected and categorized into various groups including CME, CME + resveratrol (CME + RES), CME + resveratrol+ LY294002 (CME + RES + LY), and sham groups (10 animals in each group). The inert plastic microspheres (42 μm) were injected into the rats' left ventricle for developing the CME model. Then resveratrol (25 mg/kg/d) was given to the rats in the CME + RES and CME + RES + LY groups for one week before CME induction. Furthermore, LY294002 (10 mg/kg) was intraperitoneally injected into the rats of the CME + RES + LY group 0.5 hours before CME modeling. The cardiac functions, serum levels of myocardial injury biomarkers, myocardial histopathology, and mRNA and proteins associated with myocardial apoptosis were all assessed 12 hours after surgery. RESULTS: The results revealed that resveratrol pretreatment alleviated the CME-induced myocardial damage by improving cardiac dysfunction, and lowering the serum level of myocardial injury biomarkers, myocardial microinfarct size, and cardiomyocyte apoptotic index. Pretreatment with resveratrol reduced the level of proteins and mRNAs associated with the pro-apoptosis in myocardial tissues and increased the levels of proteins and mRNAs associated with the anti-apoptosis. Moreover, the combined treatment of resveratrol and LY294002 reversed the observed protective effects. CONCLUSION: Resveratrol can inhibit cardiomyocyte apoptosis, thus attenuating the CME-induced myocardial injury by triggering the PI3K/Akt/GSK-3β cascade.
No takes yet. Share an insight, caveat, or question.
Li et al. (2021) conducted an RCT in Coronary microembolization (n=40). Resveratrol vs. CME alone, CME + RES + LY294002, and sham was evaluated on Cardiac functions, serum levels of myocardial injury biomarkers, myocardial histopathology, and mRNA and proteins associated with myocardial apoptosis. Resveratrol pretreatment alleviated coronary microembolization-induced myocardial damage by improving cardiac dysfunction and lowering myocardial injury biomarkers and microinfarct size in rats.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: